GRAIL

Menlo Park, California, United States

Precision Medicine/Diagnostics Cancer PreventionPublic

GRAIL is a healthcare company dedicated to the early detection of cancer through innovative blood-based tests. Their multi-cancer early detection (MCED) platform, including the Galleri test, aims to detect over 50 types of cancer early when it is more treatable and potentially curable.

Shareable draft

Check out GRAIL on @MedStartr Today GRAIL is a healthcare company dedicated to the early detection of cancer through innovative blood-based tests. Their multi-cancer early detection (MCED) platform, including the Galleri test, aims to detect over 50 types of cancer early when it is more treatable and potentially curable. #CancerOncology #PrecisionMedicineDiagnostics #Cancer #Prevention #MedMo #MedStartrVentures

https://www.medstartr.ai/s/Jamt7uQTn04

Get Involved in GRAIL

How We Help

Problem Statement

The problem GRAIL solves is the late detection of many deadly cancers that lack routine screening methods, leading to less effective treatments and lower survival rates. They provide a solution for early cancer detection before symptoms arise.

Core Technology

Multi-cancer early detection platform utilizing next-generation sequencing (NGS), ultra-deep sequencing of cell-free DNA (cfDNA), machine learning and artificial intelligence, and a targeted methylation-based platform.

Key Differentiators

Multi-Cancer Early Detection (MCED) from a single blood draw, robust clinical validation (large-scale studies like CCGA, NHS-Galleri, PATHFINDER, SYMPLIFY), high accuracy and low false positive rate (99.5% specificity), advanced technology integration, patient-centric approach, population-scale strategy, and comprehensive care continuum support.

Clinical Focus

Early detection of cancer, specifically multiple deadly cancer types, before symptoms arise, with the Galleri test capable of detecting over 50 types of cancer.

Target Customers

Healthcare providers (who order the test), healthcare systems, Medicare Advantage plans, and biopharmaceutical companies (for research-use-only technology).

Product Stage

Company Info

Business Model: Developing and commercializing multi-cancer early detection (MCED) blood tests, primarily the prescription-based Galleri test, generating revenue through sales and partnerships with healthcare systems/Medicare Advantage plans. They also offer a research-use-only (RUO) technology solution for biopharmaceutical companies.
Founded: 2015
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: grail.com/

Disease Areas

Cancer & Oncology

Technologies

Cell-Free DNA (cfDNA) AnalysisTargeted Methylation SequencingNext-Generation SequencingMulti-Cancer Early DetectionMachine LearningGenomic SequencingLiquid BiopsyAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

The Galleri test was designated as a 'Breakthrough Device' by the FDA in 2018. GRAIL submitted the final module of its Premarket Approval (PMA) application to the FDA on January 29, 2026. It is currently available in the U.S. as a 'laboratory developed test' (LDT) under CLIA regulations. Robust clinical validation includes large-scale studies such as CCGA, NHS-Galleri, PATHFINDER, and SYMPLIFY. An FDA-approved Investigational Device Exemption (IDE) study was initiated in November 2023. The test demonstrates high specificity of 99.5% and high accuracy (93.4% or 92%) in predicting cancer signal origin.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of GRAIL?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.